摘要
目的观察慢性阻塞性肺疾病(慢阻肺)患者使用布地奈德福莫特罗粉吸入剂治疗的临床疗效。方法根据患者治疗方式不同将2019年1~12月收治的49例慢阻肺患者分为2组,比较2组治疗前后炎性因子水平、肺功能指标、运动耐力及生活质量情况。结果治疗前2组患者炎性因子水平、肺功能情况、运动耐力情况、生活质量情况评价均差异无统计学意义(P>0.05),治疗3个月后研究组患者IL-6、IL-8水平均低于对照组,差异有统计学意义(P<0.05)、FVC、FEV1、MVV、FEV1/FVC水平均高于对照组,差异有统计学意义(P<0.05)、6MWT评价高于对照组,差异有统计学意义(P<0.05)、SGRQ总分低于对照组,差异有统计学意义(P<0.05)。结论慢阻肺患者使用布地奈德福莫特罗粉吸入剂治疗,可有效减轻机体炎性反应,促进肺功能指标恢复,提高运动耐力,改善生活质量。
Objective To investigate the curative effects of budesonide formoterol powder inhalation on chronic obstructive pulmonary disease(COPD).Methods A total of 49 patients with COPD who were admitted and treated in our hospital from January 1,2019 to December 31 were enrolled in the study,who were divided into two groups.The patients in both groups received conventional treatment,on this basis,the patients in research group were treated by budesonide formoterol powder inhalation.The levels of inflammatory factors,lung function indexes,exercise tolerance and life quality of patients before and after treatment were observed and compared between the two groups.Results Before treatment there were no significant differences in the levels of inflammatory factors,lung function,exercise endurance,and life quality of patients between the two groups(P>0.05).After 3-month treatment,the levels of IL-6 and IL-8 in research group were significantly lower than those in control group(P<0.05),however,the levels of FVC,FEV1,MVV,FEV1/FVC were significantly higher than those in control group(P<0.05).Moreover the 6 MWT evaluation in research group was superior to that in control group(P<0.05),and the total SGRQ scores were significantly lower than those in control group(P<0.05).Conclusion The budesonide formoterol powder inhalation in treatment of COPD can effectively reduce the body’s inflammatory response,promote the recovery of lung function indexes,improve exercise endurance,and improve the life quality of patients.
作者
黄芸
曹晓慧
HUANG Yun;CAO Xiaohui(Department of Respiratory Medicine,The Fourth Hospital Affiliated to Anhui Medical University,Anhui,Hefei 230022,China)
出处
《河北医药》
CAS
2020年第19期2968-2970,共3页
Hebei Medical Journal
基金
国家自然科学基金委员会资助项目计划(编号:815700341005696)。
关键词
慢阻肺
布地奈德福莫特罗粉
吸入剂
临床疗效
chronic obstructive pulmonary disease
budesonide formoterol powder
inhalation
clinical efficacy